Despite that, the total effectiveness of PI3K inhibitors in cancers is still challenging due to limited target gene engagement from the reactivation of pathways by compensatory mechanisms and crosstalks with other signaling pathways [4,20]. The gene discussed is PIK3CB; the disease is cancer.